AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Vaxcyte Inc. (PCVX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 6,822 | $388,172 | 0% | |
| 2. | Aster Capital Management (DIFC) Ltd Nabil Ouajjane | 106 | $6,031 | 0% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 937,500 | $15,000,000.00 | 5,156,553 | 2020-06-16 | Filing | |
| $16.00 | 12,500 | $200,000.00 | 4,168,718 | 2020-06-16 | Filing | |
| $16.00 | 93,000 | $1,488,000.00 | 2,222,967 | 2020-06-16 | Filing | |
| $16.00 | 250,000 | $4,000,000.00 | 2,309,554 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $61.55 | 586 | $36,066.54 | 27,860 | 2026-11-02 | Filing | |
| $60.77 | 2,414 | $146,686.71 | 28,446 | 2026-11-02 | Filing | |
| $61.57 | 343 | $21,118.51 | 145,435 | 2026-11-02 | Filing | |
| $60.78 | 1,907 | $115,905.55 | 145,778 | 2026-11-02 | Filing | |
| $86.74 | 18,000 | $1,561,320.00 | 145,435 | 2026-10-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,480,592 | $1,279,145,708 | 0.06% | |
| 2. | 3,494,748 | $198,888,568 | 0.01% | |
| 3. | 1,422,268 | $80,924,362 | 0.01% | |
| 4. | 563,323 | $32,053,078 | 0% | |
| 5. | 545,434 | $31,035,195 | 0.03% |
News See All
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
On September 3, Vaxcyte (NASDAQ:PCVX) announced two new C-suite hires and moved up the date for its most important looming catalyst.
The Next Year Will Define Vaxcyte's (PCVX) Vaccine Gamble
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict.
8 Hidden Multibagger Stocks to Buy Now
In this article, we will look at the 8 Hidden Multibagger Stocks to Buy Now.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
In this article, we will look at the 10 Most Promising Healthcare Stocks According to Wall Street Analysts.
10 Best Mid-Cap Stocks That Could Double Your Money
In this article, we will take a look at some of the best mid-cap stocks that are currently offering at least 100% upside potential to investors. On June 13, CNBC reported that U.S.
10 Best Mid Cap Stocks to Buy with Highest Upside Potential
In this article, we will discuss the 10 Best Mid Cap Stocks to Buy with Highest Upside Potential.
10 Best 52-Week High US Stocks to Buy
In this article, we will discuss the 10 Best 52-Week High US Stocks to Buy.
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2025 Earnings Call Transcript February 24, 2026Vaxcyte, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.46.
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials
Vaxcyte Inc. (NASDAQ:PCVX) is one of the best stocks to buy and hold for the next 6 months. On February 11, Vaxcyte Inc.
Hedge Fund Resource Center